News & Updates

A look back to the future in ALS research Twenty-twenty four was a busy year at NDR! We made incredible progress, but we still have far...

https://alsnewstoday.com/news/top-10-als-news-stories-2024/

https://alsnewstoday.com/news/feeding-tube-best-placed-before-major-weight-loss-als/

https://alsnewstoday.com/news/healthcare-costs-increase-als-progression-biogen-us-study/

Amyotrophic Lateral Sclerosis is a spectrum of diseases that needs a broad treatment approach Siobhan P Ellison DVM PhD1

June 21, 2024 The last subjects for the clinical trial using FC-12738, affectionally called TVALA, had their final follow up visit on ...

In hindsight, Richard Helms remembered he had a non-painful limp in 2018. After multiple consults he was introduced to ALS, that was in...

We are happy to announce the first patients are being screened for entry into the clinical trial for our drug TVALA! This Phase 1 study...

We are hopeful that TVALA will reduce p53 expression in people with ALS. There are two recent publications that give us hope. The first...

Pharmacological Characterization of FC-12738: A Novel Retro-Inverso Pentapeptide for Treating Neuroinflammation

Neurodegenerative disease research is pleased to announce the progress of developing TVALA for the treatment of neuroinflammation in ALS....

The preprint manuscript Assessment of levamisole HCl and thymosin α1 in two mouse models of amyotrophic lateral sclerosis by David R...

NDR would like to congratulate Dr. Susanne Petri and her research team on their recent paper Altered Immunomodulatory Responses in the...

Dr. Chandler Walker, associate professor in the Department of Biomedical Sciences and Comprehensive Care at Indiana University School of ...

NDR is pleased to announce research support for Ghada Maged for an ALS biomarkers project. Ms. Maged is currently completing an M. Sc....

In this final installment, Dr. Siddique delivers a personal message.

In this second installment, Dr. Siddique discusses the future of ALS research and its implications for researchers and patients. We hope...

We're pleased to announce that Northwestern University-Feinberg School of Medicine has produced a three-part video series on ALS,...

The lead molecule under development by NDR for treating neuroinflammation is the retro-inverso thymopentin, TVALA®. The application for...

NDR is pleased to congratulate Dr. Sayuri Miyamoto and her co-workers Adriano Chaves-Filho, Rosangela Santos, Rodrigo Lima, Larissa...

NDR Inc is pleased to announce that Dr. Susanne Petri has joined our scientific group. Dr. Petri is an Associate Professor in the...

New drug development

Student grants in ALS